A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.
Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal a...
Main Authors: | Frank Wegmann, George Krashias, Kerstin Lühn, Karoliina Laamanen, Sueli Vieira, Simon A Jeffs, Robin J Shattock, Quentin J Sattentau |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3017049?pdf=render |
Similar Items
-
Mucosal immunology and models of mucosal HIV infection
by: GE Griffin, et al.
Published: (1996-06-01) -
Adjuvant for vaccination against HIV-1
by: Krashias, George
Published: (2009) -
Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.
by: Viviana Buffa, et al.
Published: (2012-01-01) -
Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission.
by: Hannah M Cheeseman, et al.
Published: (2016-01-01) -
Improving defences at the portal of HIV entry: mucosal and innate immunity.
by: Robin J Shattock, et al.
Published: (2008-04-01)